Case no | Drug | Follow up after drug withdrawal (y) | LFTs | Scans5-150 | Initial histology | Follow up histology |
---|---|---|---|---|---|---|
4 | Halothane | 19.5 | Normal | Abnormal | AH | – |
7 | Diclofenac | 2.5 | Normal | Abnormal | CH | – |
8 | Diclofenac | 5.7 | Abnormal | Normal | CH | Mild inflammation |
9 | Buprenorphine | 1.7 | Abnormal | Abnormal | CH, steatosis | Steatosis |
12 | Rifampicin | 5 | Normal | Abnormal | CH, fibrosis | – |
13 | Tetracycline | 3.2 | Abnormal | Abnormal | CH, fibrosis | CH, fibrosis |
14 | Nitrofurantoin | 11.9 | Normal | Abnormal | CH, cirrhosis | – |
16 | Sulpiride | 1.3 | Abnormal | Abnormal | CH | – |
18 | Methyldopa | 7.9 | Abnormal | Abnormal | CH | CH |
19 | Amiodorone | 3.6 | Abnormal | Abnormal | CH, fibrosis | – |
21 | Co-amoxiclav | 1.8 | Abnormal | Normal | Cholestasis, ductopenia | Ductopenia |
24 | Co-amoxiclav | 3.4 | Normal | Abnormal | Cholestasis | – |
31 | Phenytoin | 2.5 | Abnormal | Abnormal | Cholestasis, fibrosis | – |
↵5-150 Isotope and ultrasound (at least one of the following three features was regarded as abnormal: uneven uptake on isotope scan; shrunken liver on ultrasound scan; or hepatomegaly with irregular texture on ultrasound scan).
LFTs, liver function tests; CH, chronic hepatitis; AH, acute hepatitis.